SLC5A2 and early-onset autosomal dominant Alzheimer disease: Therefore, APP processing control by sodium-glucose cotransporter 2 inhibitors may play a pivotal role in disease-modifying therapy for Alzheimer’s disease but also diabetes mellitus.